HC Wainwright Estimates Lipocine FY2027 Earnings

Lipocine Inc. (NASDAQ:LPCN) – Analysts at HC Wainwright issued their FY2027 EPS estimates for Lipocine in a research note issued to investors on Monday, September 21st. HC Wainwright analyst Y. Chen anticipates that the specialty pharmaceutical company will post earnings of ($1.03) per share for the year. HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Lipocine’s current full-year earnings is ($1.91) per share.

Other equities analysts also recently issued research reports about the company. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $4.00.

Lipocine Trading Up 1.4%

NASDAQ:LPCN opened at $2.24 on Tuesday. Lipocine has a 12 month low of $1.81 and a 12 month high of $12.37. The stock has a 50 day moving average of $2.19 and a two-hundred day moving average of $3.07. The firm has a market cap of $18.47 million, a P/E ratio of -1.25 and a beta of 0.47.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million.

Hedge Funds Weigh In On Lipocine

A number of institutional investors have recently added to or reduced their stakes in the stock. Eversept Partners LP acquired a new position in Lipocine in the 1st quarter valued at about $2,357,000. AIGH Capital Management LLC acquired a new position in Lipocine in the first quarter valued at approximately $1,598,000. Stempoint Capital LP purchased a new position in Lipocine in the first quarter worth approximately $1,282,000. Seven Fleet Capital Management LP acquired a new stake in Lipocine during the first quarter worth $998,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Lipocine during the fourth quarter worth $567,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.